Camrelizumab: First Global Approval, PMID: 31313098
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study, PMID: 32416073
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial, PMID: 33347829
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial, PMID: 32112738
Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma, PMID: 31039052
N-glycosylation of PD-1 promotes binding of camrelizumab, PMID: 33063473
The clinical application of camrelizumab on advanced hepatocellular carcinoma, PMID: 32762583
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial, PMID: 33087333
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial, PMID: 33166719
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial, PMID: 33052760
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials, PMID: 30213452
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial, PMID: 33172881
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients, PMID: 33241036
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial, PMID: 32393323
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma, PMID: 31420358
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy, PMID: 33323401
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma, PMID: 33314747
Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial, PMID: 32984021
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial, PMID: 32448804
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial, PMID: 32376724
Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma, PMID: 33437813
Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer, PMID: 31939448
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature, PMID: 33092443
Camrelizumab for nasopharyngeal carcinoma: a new hope?, PMID: 30213451
Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma, PMID: 32814482
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia, PMID: 32256049
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial, PMID: 32499235
Correction to: Camrelizumab: First Global Approval, PMID: 31446564
Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial, PMID: 32623573
Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation, PMID: 33004770
Antibodies to watch in 2019, PMID: 30516432
Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review, PMID: 33308041
Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report, PMID: 32110675
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy, PMID: 33154554
Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review, PMID: 32776600
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study, PMID: 30348638
Emerging agents and regimens for hepatocellular carcinoma, PMID: 31655607
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer, PMID: 30755403
Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment, PMID: 32602470
A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma, PMID: 33178785
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature, PMID: 34044548
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials, PMID: 31238988
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma, PMID: 31337439
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial, PMID: 34174189
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma, PMID: 33820822
Camrelizumab efficacious in NPC, PMID: 34253913
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?, PMID: 31950498
Camrelizumab plus famitinib to treat RCC, PMID: 34453154
Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy, PMID: 31939072
Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma, PMID: 33490196
For research use only. Not for human or drug use.
